[go: up one dir, main page]

MA44659A - Anticorps anti-tim-3 et compositions - Google Patents

Anticorps anti-tim-3 et compositions

Info

Publication number
MA44659A
MA44659A MA044659A MA44659A MA44659A MA 44659 A MA44659 A MA 44659A MA 044659 A MA044659 A MA 044659A MA 44659 A MA44659 A MA 44659A MA 44659 A MA44659 A MA 44659A
Authority
MA
Morocco
Prior art keywords
tim
antibodies
compositions
Prior art date
Application number
MA044659A
Other languages
English (en)
Other versions
MA44659B1 (fr
Inventor
Thomas Bouquin
Monika Gad
Gunther Roland Galler
Torben Gjetting
Michael Monrad Grandal
Ivan David Horak
Klaus Koefoed
Michael Kragh
Trine Lindsted
Mikkel Wandahl Pedersen
Original Assignee
Symphogen As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Symphogen As filed Critical Symphogen As
Publication of MA44659A publication Critical patent/MA44659A/fr
Publication of MA44659B1 publication Critical patent/MA44659B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA44659A 2016-04-12 2017-04-11 Anticorps anti-tim-3 et compositions MA44659B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662321476P 2016-04-12 2016-04-12
PCT/EP2017/058696 WO2017178493A1 (fr) 2016-04-12 2017-04-11 Anticorps anti-tim-3 et compositions

Publications (2)

Publication Number Publication Date
MA44659A true MA44659A (fr) 2021-04-14
MA44659B1 MA44659B1 (fr) 2021-12-31

Family

ID=58547516

Family Applications (1)

Application Number Title Priority Date Filing Date
MA44659A MA44659B1 (fr) 2016-04-12 2017-04-11 Anticorps anti-tim-3 et compositions

Country Status (35)

Country Link
US (2) US11390674B2 (fr)
EP (2) EP3443009B1 (fr)
JP (2) JP7123804B2 (fr)
KR (1) KR102473028B1 (fr)
CN (2) CN116693685A (fr)
AU (1) AU2017251250B2 (fr)
BR (1) BR112018070919A2 (fr)
CA (1) CA3020647A1 (fr)
CL (1) CL2018002878A1 (fr)
CO (1) CO2018010458A2 (fr)
CY (1) CY1125440T1 (fr)
DK (1) DK3443009T3 (fr)
EA (1) EA039020B1 (fr)
ES (1) ES2900381T3 (fr)
HR (1) HRP20211820T1 (fr)
HU (1) HUE056677T2 (fr)
IL (1) IL262176B2 (fr)
LT (1) LT3443009T (fr)
MA (1) MA44659B1 (fr)
MD (1) MD3443009T2 (fr)
MX (1) MX2018012076A (fr)
MY (1) MY199098A (fr)
PE (1) PE20181805A1 (fr)
PH (1) PH12018502112B1 (fr)
PL (1) PL3443009T3 (fr)
PT (1) PT3443009T (fr)
RS (1) RS62736B1 (fr)
SA (1) SA518400222B1 (fr)
SG (2) SG11201808724SA (fr)
SI (1) SI3443009T1 (fr)
TN (1) TN2018000333A1 (fr)
TW (1) TWI752950B (fr)
UA (1) UA126854C2 (fr)
WO (1) WO2017178493A1 (fr)
ZA (1) ZA201806429B (fr)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3274370T (lt) 2015-03-23 2020-02-10 Bayer Pharma Aktiengesellschaft Antikūnai prieš ceacam6 ir jų panaudojimas
CA3030765A1 (fr) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Anticorps anti-tim3 et leurs utilisations
PE20191741A1 (es) 2017-04-05 2019-12-12 Symphogen As Terapias combinadas dirigidas a pd-1, tim-3, y lag-3
CA3078605A1 (fr) 2017-08-28 2019-03-07 Bristol-Myers Squibb Company Antagonistes de tim-3 pour le traitement et le diagnostic de cancers
KR20200108870A (ko) 2018-01-12 2020-09-21 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
WO2019179420A1 (fr) * 2018-03-20 2019-09-26 Wuxi Biologics (Shanghai) Co., Ltd. Nouveaux anticorps anti-tim-3
AU2019236865A1 (en) 2018-03-23 2020-10-01 Bristol-Myers Squibb Company Antibodies against MICA and/or MICB and uses thereof
US11807683B2 (en) 2018-04-12 2023-11-07 Nanjing Leads Biolabs Co., Ltd. Antibody binding TIM-3 and use thereof
US11884725B2 (en) 2018-04-24 2024-01-30 Ampsource Biopharma Shanghai Inc. Antibody against TIM-3 and application thereof
CN112566936B (zh) 2018-08-21 2024-07-12 阿尔伯特爱因斯坦医学院 针对人tim-3的单克隆抗体
CN111253485A (zh) * 2018-11-30 2020-06-09 上海开拓者生物医药有限公司 抗人tim-3单克隆抗体及其应用
SG11202104518WA (en) 2018-12-19 2021-05-28 Bayer Ag Pharmaceutical combination of anti ceacam6 and tim3 antibodies
KR20220016155A (ko) 2019-05-30 2022-02-08 브리스톨-마이어스 스큅 컴퍼니 면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
JP2022534981A (ja) 2019-05-30 2022-08-04 ブリストル－マイヤーズ スクイブ カンパニー 細胞局在化シグネチャーおよび組み合わせ治療
CN114174538A (zh) 2019-05-30 2022-03-11 百时美施贵宝公司 适合于免疫肿瘤学疗法的多肿瘤基因特征
KR102536302B1 (ko) * 2020-02-25 2023-05-26 국립암센터 Tim-3 에 특이적으로 결합하는 단일클론항체 및 이의 용도
CN113214396B (zh) * 2020-07-31 2022-04-19 北京市神经外科研究所 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途
CA3190660A1 (fr) 2020-08-31 2022-03-03 George C. Lee Signature de localisation cellulaire et immunotherapie
WO2022120179A1 (fr) 2020-12-03 2022-06-09 Bristol-Myers Squibb Company Signatures géniques multi-tumorales et leurs utilisations
CA3196999A1 (fr) 2020-12-28 2022-07-07 Masano HUANG Methodes de traitement des tumeurs
AU2021411486A1 (en) 2020-12-28 2023-06-29 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
EP4314068A1 (fr) 2021-04-02 2024-02-07 The Regents Of The University Of California Anticorps dirigés contre un cdcp1 clivé et leurs utilisations
EP4326773A1 (fr) 2021-04-23 2024-02-28 Suzhou Neologics Bioscience Co., Ltd. Anticorps ciblant tim-3 et leurs utilisations
CA3222040A1 (fr) 2021-06-01 2022-12-08 Les Laboratoires Servier Anticorps anti-nkg2a et compositions
WO2023031366A1 (fr) 2021-09-02 2023-03-09 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Anticorps anti-cecam6 à effets secondaires réduits
JP2024532461A (ja) 2021-09-03 2024-09-05 オンコワン・リサーチ・アンド・ディベロップメント・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 低減された凝集能及び低減された疎水性を有する、改善されたＦｃサイレンシングされた抗ｏｘＭＩＦ抗体
KR20240159621A (ko) 2022-03-18 2024-11-05 브리스톨-마이어스 스큅 컴퍼니 폴리펩티드를 단리하는 방법
AU2023281061A1 (en) 2022-06-02 2024-12-05 Bristol-Myers Squibb Company Antibody compositions and methods of use thereof
WO2024224323A1 (fr) 2023-04-24 2024-10-31 King Abdullah University Of Science Of Technology Compositions, systèmes et procédés de détection multiplex de biomarqueurs cibles dans un échantillon
CN118373913B (zh) * 2024-05-08 2024-11-01 上海百英生物科技股份有限公司 一种抗人Tim-3单克隆抗体及其制备方法
CN118165111B (zh) * 2024-05-15 2024-08-13 中国人民解放军军事科学院军事医学研究院 针对Tim-3的抗体

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
GB2183662B (en) 1985-04-01 1989-01-25 Celltech Ltd Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
CA2341029A1 (fr) 1998-08-17 2000-02-24 Abgenix, Inc. Production de molecules modifiees avec demi-vie serique prolongee
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
EP2252319A2 (fr) 2008-01-29 2010-11-24 The Brigham and Women's Hospital, Inc. Procédés pour moduler une population de cellules myéloïdes suppressives et leurs utilisations
WO2010084999A1 (fr) 2009-01-26 2010-07-29 Protegene, Inc. Agents immunosuppresseurs et agents prophylactiques et thérapeutiques pour des maladies auto-immunes
ES2571235T3 (es) 2009-04-10 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para el tratamiento de un tumor sanguíneo que utiliza el anticuerpo anti-TIM-3
ES2682078T3 (es) * 2010-06-11 2018-09-18 Kyowa Hakko Kirin Co., Ltd. Anticuerpo anti-TIM-3
JP2013532153A (ja) 2010-06-18 2013-08-15 ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッド 慢性免疫病に対する免疫治療のためのｔｉｍ−３およびｐｄ−１に対する二重特異性抗体
US8841418B2 (en) 2011-07-01 2014-09-23 Cellerant Therapeutics, Inc. Antibodies that specifically bind to TIM3
US10570204B2 (en) 2013-09-26 2020-02-25 The Medical College Of Wisconsin, Inc. Methods for treating hematologic cancers
CN103936853B (zh) 2014-01-26 2016-08-17 中国人民解放军军事医学科学院基础医学研究所 一种检测tim-3试剂盒及其使用方法
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN106687125B (zh) 2014-03-12 2021-12-14 耶达研究与开发有限公司 降低系统性调节性t细胞水平或活性来治疗cns疾病和损伤
ES2851451T3 (es) 2014-05-13 2021-09-07 Bavarian Nordic As Terapia de combinación para tratar cáncer con un poxvirus que expresa un antígeno de tumor y un anticuerpo monoclonal contra TIM-3
US20160200815A1 (en) 2015-01-05 2016-07-14 Jounce Therapeutics, Inc. Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof
MX2017011406A (es) * 2015-03-06 2018-06-19 Sorrento Therapeutics Inc Terapeuticos de anticuerpo que se unen a tim3.
US20180207273A1 (en) 2015-07-29 2018-07-26 Novartis Ag Combination therapies comprising antibody molecules to tim-3
US11014983B2 (en) 2015-08-20 2021-05-25 Sutro Biopharma, Inc. Anti-Tim-3 antibodies, compositions comprising anti-Tim-3 antibodies and methods of making and using anti-Tim-3 antibodies
WO2017055404A1 (fr) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anticorps bispécifiques spécifiques de pd1 et tim3
CA3030765A1 (fr) 2016-07-14 2018-01-18 Bristol-Myers Squibb Company Anticorps anti-tim3 et leurs utilisations
JOP20190013A1 (ar) 2016-08-25 2019-01-31 Lilly Co Eli أجسام مضادة لـ (تي آي ام -3)
JOP20190133A1 (ar) 2016-12-08 2019-06-02 Innovent Biologics Suzhou Co Ltd أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1
PE20191741A1 (es) 2017-04-05 2019-12-12 Symphogen As Terapias combinadas dirigidas a pd-1, tim-3, y lag-3
JOP20190222A1 (ar) 2017-04-11 2019-09-24 Zymeworks Inc الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3

Also Published As

Publication number Publication date
CA3020647A1 (fr) 2017-10-19
JP2022172142A (ja) 2022-11-15
SG10201912937SA (en) 2020-02-27
AU2017251250A1 (en) 2018-10-18
JP7123804B2 (ja) 2022-08-23
SG11201808724SA (en) 2018-11-29
CL2018002878A1 (es) 2019-04-26
HRP20211820T1 (hr) 2022-03-04
EP3443009A1 (fr) 2019-02-20
EA039020B1 (ru) 2021-11-23
TWI752950B (zh) 2022-01-21
LT3443009T (lt) 2021-12-27
US20230105714A1 (en) 2023-04-06
DK3443009T3 (da) 2021-12-13
US11390674B2 (en) 2022-07-19
EP3443009B1 (fr) 2021-09-08
PH12018502112B1 (en) 2024-03-27
KR102473028B1 (ko) 2022-11-30
KR20180133482A (ko) 2018-12-14
WO2017178493A1 (fr) 2017-10-19
HUE056677T2 (hu) 2022-02-28
EP3978531A1 (fr) 2022-04-06
PT3443009T (pt) 2021-12-10
CY1125440T1 (el) 2023-03-24
ES2900381T3 (es) 2022-03-16
AU2017251250B2 (en) 2024-03-21
CN116693685A (zh) 2023-09-05
MA44659B1 (fr) 2021-12-31
PE20181805A1 (es) 2018-11-19
TW201736397A (zh) 2017-10-16
SI3443009T1 (sl) 2022-04-29
MX2018012076A (es) 2019-02-20
BR112018070919A2 (pt) 2019-01-29
SA518400222B1 (ar) 2022-03-14
UA126854C2 (uk) 2023-02-15
CO2018010458A2 (es) 2018-10-10
US20190276531A1 (en) 2019-09-12
IL262176B2 (en) 2023-03-01
CN109451741A (zh) 2019-03-08
TN2018000333A1 (en) 2020-01-16
JP2019519199A (ja) 2019-07-11
PH12018502112A1 (en) 2019-09-23
PL3443009T3 (pl) 2022-01-31
IL262176A (en) 2018-11-29
CN109451741B (zh) 2023-07-28
MY199098A (en) 2023-10-12
IL262176B (en) 2022-11-01
ZA201806429B (en) 2023-02-22
EA201892294A1 (ru) 2019-04-30
MD3443009T2 (ro) 2022-02-28
RS62736B1 (sr) 2022-01-31

Similar Documents

Publication Publication Date Title
MA46525A (fr) Anticorps anti-lag-3 et compositions
MA44659A (fr) Anticorps anti-tim-3 et compositions
MA47694A (fr) Anticorps anti-tigit
MA49034A (fr) Anticorps anti-lag3
MA47268A (fr) Anticorps anti-gpc3
EP3423089A4 (fr) Anticorps anti-tigit
HK1252976A1 (zh) 抗cd123抗體以及其綴合物和衍生物
HK1251587A1 (zh) 抗磷脂酰肌醇蛋白多糖-3的抗體及其應用
KR102162129B9 (ko) 항-갈렉틴-9 항체 및 이의 용도
IL262095A (en) Anti-pacap antibodies and uses thereof
EP3307274A4 (fr) Anticorps anti-cd123 et conjugués de ceux-ci
EP3334757A4 (fr) Anticorps anti-tigit
EP3693391C0 (fr) Anticorps et immunoconjugués anti-cll-1
MA45004A (fr) Anticorps spécifiques anti-wt1-hla
MA46057A (fr) Anticorps anti-ctla4
DK3368572T3 (da) Anti-pd-1-antistoffer og -sammensætninger
EP3316909A4 (fr) Anticorps anti-ntb-a ainsi que compositions et procédés associés
EP3334824A4 (fr) Anticorps anti-pd-1
MA49726A (fr) Formulation d'anticorps anti-cgrp
MA50352A (fr) Anticorps multispécifiques
EP3359573A4 (fr) Marquage d'anticorps
EP3353213A4 (fr) Nouvel anticorps anti-mésothéline et composition le comprenant
MA46272A (fr) Anticorps anti-cd27
MA47472A (fr) Anticorps
DK3504241T3 (da) Anti-cd3-antistofformuleringer